


## Meeting the Editorial Advisory Board

---


Editorial advisors representing diverse areas in the pharmaceutical sciences from North America, Europe, and Asia are appointed for a three-year term. In addition to his/her customary advisory function to the editorial team, each member has the additional responsibility of reviewing 12 manuscripts within two weeks of receipt for the journal. Those members

with expertise in computational chemistry and biology, molecular biology and pharmacology, clinical pharmacology, pharmacoeconomics, pharmacoepidemiology, or disease state management are appointed to help grow these currently underrepresented areas in the journal. Future board members will be recruited from the reviewer pool.

---



Michael B. Bolger is an Associate Professor of Pharmaceutical Sciences at the University of Southern California. He obtained his Ph.D. degree in Pharmaceutical Chemistry at UC San Francisco in 1978. His basic research is focused on neurological disorders, with the goal to develop novel strategies for therapeutic drug design and testing. The disciplines of chemistry, pharmacology, and molecular biology have been applied to the design, synthesis, and pharmacological testing of agents useful in the treatment of infantile spasms, epilepsy, anxiety, and insomnia. State of the art techniques in computational chemistry and molecular graphics are applied to all aspects of drug design and modeling of drug receptor interactions.



Richard N. Dalby is an Assistant Professor in the Department of Pharmaceutical Sciences, University of Maryland at Baltimore, and an Affiliate Associate Professor in the Department of Pharmacy and Pharmaceutics at Medical College of Virginia/VCU. Dr. Dalby holds a Bachelor of Phar-

macy degree (1983) from Nottingham University, and a Ph.D. in Pharmaceutical Sciences from the University of Kentucky (1988). He has numerous papers, abstracts and patents related to aerosol technology, and organizes a popular annual workshop for industrial scientists on this increasingly important method of drug delivery.




Hans E. Junginger graduated in Pharmacy at the University of Munich, Germany, in 1967 and obtained his Ph.D. degree in Pharmaceutical Chemistry at the University of Saarbrücken, Germany in 1971. In 1981 he was appointed head of the Department of Pharmaceutical Technology at Leiden University, The Netherlands. He currently holds this position at the Leiden/Amsterdam Center for Drug Research. His research interests are: colloidal structures of semi-solids; their interactions with skin, peroral, buccal and transdermal (iontophoretic) peptide drug delivery and absorption, and the use of vesicular drug carriers for (trans)dermal application and peroral vaccination.



William J. Jusko is Professor of Pharmaceutics at the State University of New York at Buffalo where he obtained his BS


in Pharmacy (1965) and Ph.D. (1970) degrees. He was a Fulbright Scholar at The Mario Negri Institute for Pharmacology in Italy in 1978/79, received the Rawls-Palmer Award in 1987 from the ASCPET, the Doctor Honoris Causae from the Medical Academy of Cracow in 1987, the Russell R. Miller Award from the ACCP in 1988, and the Distinguished Services Award from the American College of Clinical Pharmacology in 1989. His research interests involve clinical, basic, and theoretical pharmacokinetics and pharmacodynamics of diverse drugs, particularly corticosteroids and antidepressants.



Thomas H. Kissel has been Professor of Pharmaceutics and Biopharmacy at the Philipps-University, Marburg, since 1991. He was formerly head of the multidisciplinary drug delivery systems department and vice president at Sandoz Pharma in Basle, Switzerland. He has authored more than 100 publications in parenteral delivery systems, biodegradable polymers, transepithelial transport and peptide delivery systems. He received his B.A. in Pharmacy from Freiburg in 1971, M.A. in Chemistry from Marburg in 1974, and Ph.D. in Medical Chemistry from Marburg in 1976.



Peter Kollman received his Ph.D. in Chemistry from Princeton University in 1970. He is Professor of Chemistry and Pharmaceutical Chemistry at the University of California, San Francisco. His research interests are in the study of molecular interactions in condensed phases using computer based approaches.



Thomas M. Ludden received a B.S. in Pharmacy (1969) and Ph.D. in Pharmacology (1973) from the University of Missouri-Kansas City. After postdoctoral training at Ohio State University, Dr. Ludden joined the faculty of the College of Pharmacy, University of Texas-Austin in 1975. In 1991, he joined the Division of Biopharmaceutics, Food and Drug Administration, where he was Director of that division until his appointment as Parke Davis Professor and Chairman, Department of Pharmaceutical Sciences at the University of Nebraska Medical Center in 1995. His interest is in the use of pharmacokinetics and pharmacodynamics to improve both the efficiency of drug development and the individualization of drug therapy.




Hans P. Merkle holds the Chair of Pharmaceutics at the Swiss Federal Institute of Technology Zurich (ETH). He has previously been a Professor of Pharmaceutics at Bonn University and at Frankfurt University in Germany. The current research focus of his group is in the areas of (i) pathways of transport and metabolism of therapeutic peptides and proteins in epithelial barriers, e.g., the intestine, nasal mucosa, and skin, (ii) formulation aspects of biopharmaceutics, (iii) sustained delivery of antigens, and (iv) biocompatible materials for drug delivery.




Kamal K. Midha, Ph.D., D.Sc., is Professor of Pharmacy and Adjunct Professor of Psychiatry at the University of

Saskatchewan, Canada, where he is also head of the Drug Metabolism, Drug Disposition Group. He is Chairman of the Board of Pharmaceutical Sciences of the International Pharmaceutical Federation (FIP). His main areas of interest include investigations towards the more efficacious use of psychotropic drugs, drug metabolism and disposition, intra-subject variability in pharmacokinetics and pharmacodynamics, especially of highly variable drugs, and issues related to bioavailability and bioequivalence.



Duane D. Miller is the Van Vleet Professor in the College of Pharmacy, University of Tennessee at Memphis. He obtained his Ph.D. degree from the University of Washington. He has published extensively in the design and synthesis of new drugs for asthma, emphysema, Parkinson's disease, schizophrenia, drug addiction, diabetes, sedation and anesthesia.



Randall Mrsny obtained a B.S. in Biochemistry and Biophysics at U.C. Davis, followed by a Ph.D. in Anatomy and Cell Biology at the U.C. Davis Medical School and an NIH postdoctoral fellowship at the University of Oregon's Institute of Molecular Biology. Currently, he heads the Drug Delivery/Biology Group at Genentech, Inc., where he studies issues related to the barrier function and properties of epithelial cells.



Bernd W. Müller is Professor of Pharmaceutics and Biopharmaceutics at Christian-Albrecht University of Kiel, Ger-


many. The first European co-editor of *Pharmaceutical Research*, his research interests are in solubilization of sparingly soluble drugs, drug targeting, microspheres and biodegradable polymers, nasal and oral peptide absorption, dermal drug absorption, and sponges as drug carrier systems.




Masahiro Nakano is currently Professor of Clinical Pharmacy at Kumamoto University School of Medicine with a joint appointment of Director of Pharmaceutical Sciences at Kumamoto University Hospital. He earned his M.S. degree in Pharmacy from Kyoto University and his Ph.D. degree in Pharmacy from the University of Wisconsin under the Fulbright program. His research interests are in the disposition of drugs in humans and in the development of dosage forms for poorly orally available drugs.




Joseph R. Robinson is Professor of Pharmacy, School of Pharmacy, University of Wisconsin-Madison. A graduate of Columbia University College of Pharmacy (B.S. M.S.) and the University of Wisconsin (Ph.D.), he has served on the faculty at Madison, Wisconsin since 1966. Dr. Robinson is a past-president of the Controlled Release Society (CRS) and the American Association of Pharmaceutical Scientists (AAPS). The holder of an honorary doctorate degree from the Royal Danish School of Pharmacy (1992) and the recipient of numerous international awards, prizes, and named lectureships, his research interests are in the areas of controlled drug delivery, ocular drug disposition, and bioadhesives.



Wolfgang Sadée received his doctorate degree in pharmaceutical chemistry from the Free University, Berlin, in 1968. He has been on the faculty at the School of Pharmacy, University of California at San Francisco since 1973. The founding editor of *Pharmaceutical Research*, his main research areas include molecular pharmacology, biology of neurotransmitter receptors, e.g., the opioid, muscarinic and dopamine receptors, and molecular genetics of intestinal dipeptide transporters relevant to peptoid drug absorption.




Valentino J. Stella is University Distinguished Professor of Pharmaceutical Chemistry and Director of the Center for Drug Delivery Research at the University of Kansas. He is also Victorian Professor of Pharmaceutics at the Victorian College of Pharmacy, Melbourne, Australia. Professor Stella's major research interests are in the area of the application of physical/organic chemistry to the study of factors affecting drug delivery. Specifically, he is working in the areas of chemical kinetics, preformulation work-up of cytotoxic and anti-AIDS drugs, improved drug delivery through the use of prodrugs and cyclodextrins, and the mechanism of lymphatic drug transport.




Andy Stergachis, Ph.D., is Chairman and Professor of Pharmacy, School of Pharmacy and Professor of Epidemiology,

School of Public Health and Community Medicine at the University of Washington, Seattle, WA. He also directs the Program in Pharmaceutical Outcomes Research and Policy. His educational background includes a pharmacy degree from Washington State University and an M.S. and a Ph.D. in Social and Administrative Pharmacy from the University of Minnesota. He is a past recipient of the Burroughs Wellcome Scholar Award and the AAPS Research Achievement Award in Economic, Marketing and Management Sciences. His primary research interests are in pharmaceutical outcomes, including pharmacoepidemiology and cost-effectiveness analyses, and clinical epidemiology.




Robert J. Wills is Vice President, Project Planning and Management, at The R.W. Johnson Pharmaceutical Research Institute (PRI). He received his B.S. in Biochemistry (1976) and M.S. in Pharmaceutics (1979) from the University of Wisconsin, and his Ph.D. in Pharmaceutics (1981) from The University of Texas. A former Associate Editor of *Pharmaceutical Research*, Dr. Wills is the author of over fifty research publications and book chapters in the area of clinical pharmacokinetics/pharmacodynamics.



R.L. Juliano is Professor and Chairman in the Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill. His research interests are in cell adhesion receptors and signal transduction; transport and delivery of drugs, especially antisense oligonucleotides; and cancer biology and therapeutics.



Gordon McKay received a B.Sc. degree and Ph.D. degree in Biochemistry from the University of Saskatchewan in Canada. He is a Professor in the College of Pharmacy and Nutrition at the University of Saskatchewan. His research interests lie in the area of development and application of ultrasensitive analytical procedures for drugs and their metabolites.



Professor Alexander T. (Sandy) Florence is Dean of the School of Pharmacy in the University of London where his research group is part of the Centre for Drug Delivery Research. Prior to his move to London he was, from 1975–1988, Professor of Pharmaceutics at the University of Strathclyde in Glasgow, Scotland. His research interests are in surfactant and colloid chemistry as applied to drug delivery, concentrating now on surfactant vesicle behaviour, responsive hydrogels and nanoparticulate uptake from the gut. He has a broader interest in the application of the pharmaceutical sciences to practice.

***Board Member with Biographical Sketch but no Photo***


Timothy S. Wiedmann received his B.S. (1980), M.S. (1983), and Ph.D. (1985) in Pharmacy from the University of Wisconsin-Madison. Thereafter he was a postdoctoral fellow in the Department of Chemistry and Biophysics at the University of Virginia in Charlottesville. He joined the College of Pharmacy at the University of Minnesota in 1987 and is currently an Associate Professor in the Department of Pharmaceutics. His research interests include characterization of

lipid membranes, lipid-protein systems, and lipid micelles by traditional physical chemical and innovative spectroscopic techniques for pharmaceutical applications in oral, transdermal and respiratory drug delivery.

***Board members with no Biographical Sketches and Photos***

John G. Gambertoglio  
Susan Hershenson  
Myron K. Jacobson

The following Board Members' Photos appeared in *Pharmaceutical Research* 12, 1559 (1995) with the incorrect Biographical Sketches. Below are the Photos and Biographical Sketches as they should appear.



Harold G. Boxenbaum is Director of Pharmacokinetics at Otsuka America Pharmaceuticals, Inc. in Rockville, Maryland. His researches interest include clinical pharmacology in drug development, interspecies pharmacokinetic scaling and longevity hormesis (paradoxical life prolongation by low doses of toxic agents).



Robert Gurny is Professor and Head of the Department of Biopharmaceutics and Physical Pharmacy at the University of Geneva, Switzerland where he earned both his BS in pharmacy and his Ph.D. in physical pharmacy. He later earned a degree in statistics and computer science. Dr. Gurny's major research interests include pharmaceutical processing and the use of polymers in the design of new controlled-drug-release systems.